Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Breast neoplasms
Disease-free survival
Magnetic resonance imaging
Neoadjuvant therapy
Prognosis
Journal
Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
28
12
2021
revised:
08
04
2022
accepted:
10
04
2022
pubmed:
19
5
2022
medline:
5
10
2022
entrez:
18
5
2022
Statut:
ppublish
Résumé
The purpose of this study was to retrospectively investigate whether background parenchymal enhancement (BPE) of the contralateral breast on magnetic resonance imaging (MRI) is associated with clinical outcomes in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy (NAC). A total of 228 women (47.6 years ± 10 [SD]; range: 24-74 years) with invasive breast cancer who underwent NAC between 2005 and 2013 were included. All included patients underwent breast MRI before and after NAC. Quantitative semiautomated analysis of BPE of the contralateral healthy breast was performed. The enhancement level on baseline MRI (baseline BPE) and on MRI after chemotherapy (final BPE) and the change in enhancement rate between baseline MRI and final MRI were recorded. Cox regression was used to test associations between BPE variables, patient and tumor characteristics, overall survival (OS) and disease-free survival (DFS). Subgroup analyses based on menopausal status and immunohistochemical subtypes were performed. Median follow-up was 92 months. Multivariable analysis revealed that Ki-67 level (P = 0.026) and receipt of mastectomy (P = 0.015) were independent variables associated with OS while Ki-67 level (P = 0.010) and post-NAC pathological node categorization (P = 0.027) were independent variables associated with DFS. BPE was not associated with OS (P = 0.500, 0.546 and 0.712 for baseline BPE, final BPE and BPE change, respectively) or with DFS (P = 0.568, 0.412 and 0.327, respectively). BPE of the contralateral breast on MRI may have limited prognostic value in patients with breast cancer treated with NAC.
Identifiants
pubmed: 35585020
pii: S2211-5684(22)00074-2
doi: 10.1016/j.diii.2022.04.004
pii:
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-494Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declarations of Competing Interest The authors declare that they have no conflict of interest to disclose in relation with this article.